GSK plc with ticker (LON:GSK) now has a potential upside of 13.1% according to Deutsche.
Deutsche set a target price of 1,700 GBX for the company, which when compared to the GSK plc share price of 1,503 GBX at opening today (19/09/2023) indicates a potential upside of 13.1%. Trading has ranged between 1,281 (52 week low) and 1,609 (52 week high) with an average of 5,751,097 shares exchanging hands daily. The market capitalisation at the time of writing is £61,154,969,943.
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
GSK plc 13.1% potential upside indicated by Deutsche
- Written by: Charlotte Edwards
Latest Company News
GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and over.
GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients.
GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026.
GSK has announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has been granted Orphan Drug Designation by the US FDA for small-cell lung cancer.
TESARO, part of GSK, has filed a case in the Delaware Chancery Court claiming AnaptysBio has breached its licence agreement for the cancer treatment Jemperli.
GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines.
